XML 48 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Reportable Segment Information (Tables)
6 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
Summary of Financial Information for Each Reportable Segment

The following table presents various financial information for each reportable segment for the three and six months ended March 31, 2022 and 2021.

 

Three months ended

 

 

Six months ended

 

 

March 31

 

 

March 31

 

(In millions - unaudited)

2022

 

 

2021

 

 

2022

 

 

2021

 

SALES

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

204

 

 

$

185

 

 

$

374

 

 

$

355

 

Personal Care

 

172

 

 

 

137

 

 

 

318

 

 

 

262

 

Specialty Additives

 

182

 

 

 

158

 

 

 

338

 

 

 

305

 

Intermediates

 

66

 

 

 

37

 

 

 

119

 

 

 

69

 

Intersegment sales (a)

 

(20

)

 

 

(8

)

 

 

(34

)

 

 

(14

)

 

$

604

 

 

$

509

 

 

$

1,115

 

 

$

977

 

OPERATING INCOME (LOSS)

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

43

 

 

$

35

 

 

$

64

 

 

$

64

 

Personal Care

 

28

 

 

 

19

 

 

 

42

 

 

 

33

 

Specialty Additives (b)

 

26

 

 

 

19

 

 

 

44

 

 

 

21

 

Intermediates

 

27

 

 

 

3

 

 

 

42

 

 

 

5

 

Unallocated and other

 

(31

)

 

 

(28

)

 

 

(57

)

 

 

(57

)

 

$

93

 

 

$

48

 

 

$

135

 

 

$

66

 

DEPRECIATION EXPENSE

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

8

 

 

$

8

 

 

$

16

 

 

$

17

 

Personal Care

 

9

 

 

 

9

 

 

 

18

 

 

 

19

 

Specialty Additives

 

17

 

 

 

16

 

 

 

33

 

 

 

33

 

Intermediates

 

3

 

 

 

4

 

 

 

7

 

 

 

6

 

 

$

37

 

 

$

37

 

 

$

74

 

 

$

75

 

AMORTIZATION EXPENSE

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

7

 

 

$

7

 

 

$

14

 

 

$

14

 

Personal Care

 

12

 

 

 

10

 

 

 

24

 

 

 

19

 

Specialty Additives

 

5

 

 

 

5

 

 

 

9

 

 

 

9

 

Intermediates

 

 

 

 

 

 

 

 

 

 

1

 

 

$

24

 

 

$

22

 

 

$

47

 

 

$

43

 

EBITDA (c)

 

 

 

 

 

 

 

 

 

 

 

Life Sciences

$

58

 

 

$

50

 

 

$

94

 

 

$

95

 

Personal Care

 

49

 

 

 

38

 

 

 

84

 

 

 

71

 

Specialty Additives

 

48

 

 

 

40

 

 

 

86

 

 

 

63

 

Intermediates

 

30

 

 

 

7

 

 

 

49

 

 

 

12

 

Unallocated and other

 

(31

)

 

 

(28

)

 

 

(57

)

 

 

(57

)

 

$

154

 

 

$

107

 

 

$

256

 

 

$

184

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31

 

 

September 30

 

(In millions - unaudited)

2022

 

 

2021

 

TOTAL ASSETS

 

 

 

 

 

Life Sciences

$

1,940

 

 

$

1,945

 

Personal Care

 

1,114

 

 

 

1,145

 

Specialty Additives

 

1,638

 

 

 

1,636

 

Intermediates

 

175

 

 

 

160

 

Unallocated and other

 

1,913

 

 

 

1,726

 

 

$

6,780

 

 

$

6,612

 

 

 

 

 

 

 

(a)
Intersegment sales from Intermediates are accounted for at prices that approximate fair value. All other intersegment transfers are accounted for at cost.
(b)
Includes a capital project impairment of $9 million for the six months ended March 31, 2021 relating to a long-term capital project plan change at a plant facility.
(c)
Excludes income (loss) from discontinued operations, other net periodic benefit income (expense) and net income (loss) on divestitures. See the Statement of Consolidated Comprehensive Income (Loss) for applicable amounts excluded.